NCT03634137View on ClinicalTrials.gov

Implant Pharmacokinetic and Pharmacodynamic Study

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

March 31, 2010

Conditions
Healthy
Interventions
DRUG

Afamelanotide Group 1

One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.

DRUG

Afamelanotide Group 2

One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.

Trial Locations (1)

55114

Prism Research Inc., Saint Paul

Sponsors
All Listed Sponsors
lead

Clinuvel Pharmaceuticals Limited

INDUSTRY